FDA Approval: Adjuvant Alectinib for Resected NSCLC

episode

Lung Cancer Considered not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Finance and Budget Committee - Sep 15, 2026 1h 43m · 15 Sep 2026 · Prince William County Finance and Budget Committee

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

The Chris Wolfe Podcast: The Power of Quality Supplements 48 min · 14 Sep 2026 · EyeCode Media

1208: TM Europe win the '26 Solheim Cup 1h 49m · 13 Sep 2026 · No Laying Up - Golf Podcast

MORNING TEA: Harry & Meghan's Brutal SNL Roast, Lady Gaga's Baby News & Dakota Johnson's New Man 8 min · 13 Sep 2026 · The Spill

"I don't think they have enough match winners."| First Thoughts - Brisbane vs Adelaide (14.09.26) 15 min · 13 Sep 2026 · SEN Breakfast

Report any issue

Source

Recorded18 Apr 2024

Publisherfeeds.soundcloud.com ↗

Handlerec:2151487

Show notes

In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related